InsiderTradesSIGMA

PicksTOP Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FRUSDEGBCHCAITESNLBENOSEFIDKAUATIEBRINJP+ 8 markets

Recommendations
Companies
Insiders
Performance
Backtest
Compare

Markets
Sectors
Top movers
Leaderboard
Clusters
Heatmap
Earnings radar
Archive

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

Theme: dark (range regime detected on CAC40 90d · as of 2026-05-26)

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

All systems operational

InsidersTradesSigma

IT IT1,445 companies

IT-Listed Companies

Regulator: Consob.

PHARMANUTRA PHARMANUTRA PHN - RICAVI PRELIMINARI 2025

PHARMANUTRA PHARMANUTRA PHN - RICAVI PRELIMINARI 2025

Healthcare · 862m

PHARMANUTRA PHARMANUTRA S.P.A.: AL VIA IN MESSICO LA DISTRIBUZIONE DEI COMPLEMENTI NUTRIZIONALI A BASE DI FERRO

PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025

PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025

Healthcare · 862m

PHARMANUTRA PHARMANUTRA S.P.A.: FIRST SIGNIFICANT SALES RESULTS IN CHINA

PHARMANUTRA PHARMANUTRA S.P.A.: LE NOVITA SUI MERCATI ESTERI

← PreviousPage 22 of 29Next →

PHARMANUTRA PHARMANUTRA S.P.A.: NEWS AND UPDATES ON FOREIGN MARKETS

—

PHARMANUTRA PHARMANUTRA S.P.A.: THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO

PHARMANUTRA PHARMANUTRA_PR

PHARMANUTRA PHN

PHARMANUTRA PHN - RICAVI PRELIMINARI 2023

Healthcare · 862m

Healthcare · 862m

PHARMANUTRA PR - PHARMANUTRA - PHN - CETILAR SIDE BY SIDE WITH FERNANDO ALONSO

PHARMANUTRA PR - PHN PRELIMINARY REVENUES 2023

Healthcare · 862m

PHARMANUTRA PR - PHN PRELIMINARY REVENUES 2023

PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT

PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT

Healthcare · 862m

PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023

Healthcare · 862m

PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023

Consumer Cyclical · 602m

Consumer Cyclical · 602m

PIAGGIO & C. CS

PIAGGIO & C. CS GRUPPO PIAGGIO - PROGETTO DI BILANCIO 2023

Consumer Cyclical · 602m

PIAGGIO & C. CS GRUPPO PIAGGIO - PROGETTO DI BILANCIO 2023

PIAGGIO & C. CS GRUPPO PIAGGIO: RISULTATI AL 30 SETTEMBRE 2024

PIAGGIO & C. CS GRUPPO PIAGGIO: RISULTATI AL 30 SETTEMBRE 2024

Consumer Cyclical · 602m

PIAGGIO & C. GRUPPO PIAGGIO: CONSIGLIO DI AMMINISTRAZIONE

Consumer Cyclical · 59m

Consumer Cyclical · 124m

Consumer Cyclical · 6.5bn

Consumer Cyclical · 6.5bn

PIRELLI & C. PIRELLI & C. SPA BOARD REVIEWED CONSOLIDATED RESULTS TO 30 SEPTEMBER 2023

Consumer Cyclical · 6.5bn

PIRELLI & C. PIRELLI & C. SPA BOARD REVIEWED CONSOLIDATED RESULTS TO 30 SEPTEMBER 2023

PIRELLI & C. PIRELLI & C. SPA BOARD REVIEWS CONSOLIDATED RESULTS TO 31 MARCH 2024

Consumer Cyclical · 6.5bn

PIRELLI & C. PIRELLI & C. SPA BOARD REVIEWS CONSOLIDATED RESULTS TO 31 MARCH 2024

PIRELLI & C. PIRELLI: INDUSTRIAL PLAN UPDATE 2024-25 E BUDGET 2024

Consumer Cyclical · 6.5bn

PIRELLI & C. PIRELLI: INDUSTRIAL PLAN UPDATE 2024-25 E BUDGET 2024

PIRELLI & C. PIRELLI: PROPOSED ESTABLISHMENT OF CORPORATE GENERAL MANAGEMENT TO BE HEADED BY FRANCESCO TANZI

PIRELLI & C. PIRELLI: REVIEW OF PRELIMINARY RESULTS TO 31 DECEMBER 2024 AND APPROVAL OF 2025 BUDGET

Consumer Cyclical · 6.5bn

PIRELLI & C. PIRELLI: REVIEW OF PRELIMINARY RESULTS TO 31 DECEMBER 2024 AND APPROVAL OF 2025 BUDGET

PIRELLI & C. REVIEW OF PRELIMINARY RESULTS TO 31 DECEMBER 2025 AND 2026 BUDGET

Consumer Cyclical · 6.5bn

PIRELLI & C. REVIEW OF PRELIMINARY RESULTS TO 31 DECEMBER 2025 AND 2026 BUDGET

PIRELLI & C. THE BOARD OF PIRELLI & C. S.P.A. HAS APPROVED RESULTS TO 31 DECEMBER 2023

Consumer Cyclical · 6.5bn

PIRELLI & C. THE BOARD OF PIRELLI & C. S.P.A. HAS APPROVED RESULTS TO 31 DECEMBER 2023

PIRELLI & C. THE BOARD OF PIRELLI & C. SPA REVIEWED CONSOLIDATED RESULTS TO 30 JUNE 2023

Consumer Cyclical · 6.5bn